Rivaroxaban Dosing for DVT in Elderly Patients with Renal Impairment

Initial Treatment and Maintenance Phases

The American College of Cardiology recommends administering rivaroxaban 15 mg orally twice daily with food for the first 21 days for acute DVT treatment in elderly patients with moderate renal impairment, followed by 15 mg once daily for maintenance therapy 1
For patients with eGFR 30-49 mL/min, the maintenance dose should be reduced to 15 mg once daily, as the standard 20 mg dose significantly increases bleeding risk 2
Rivaroxaban has 66% renal excretion, making it highly dependent on kidney function, and dose adjustments are necessary in patients with moderate renal impairment 3

The combination of rivaroxaban and clopidogrel substantially increases bleeding risk and should be avoided unless there is a specific cardiovascular indication, such as recent acute coronary syndrome or PCI within the past year 1, 2
If dual therapy is necessary, limit clopidogrel duration to the minimum necessary and use the reduced 15 mg daily maintenance dose of rivaroxaban, with intensified bleeding surveillance 1, 2

Assess renal function 2-3 times per year in patients with moderate renal impairment, and monitor for declining renal function that could necessitate further dose adjustment or drug discontinuation 2, 3
Educate patients to immediately report unusual bruising or bleeding, blood in urine or stool, black tarry stools, coughing or vomiting blood, severe headache, dizziness, or weakness, and any falls or head trauma 2, 4

For unprovoked DVT or DVT with persistent risk factors, offer extended-phase anticoagulation beyond the initial 3-6 months, and consider reducing to rivaroxaban 10 mg once daily for extended secondary prevention 4, 5
Avoid using the standard 20 mg maintenance dose in patients with CrCl 30-49 mL/min, and do not combine rivaroxaban with antiplatelet agents unless there is a compelling recent cardiovascular indication requiring dual therapy 2